AKT1 and cancer: This PI3K inhibitor exhibits potential as a targeted therapy for dogs with PIK3CA mutations: in vitro effects demonstrated its capacity to inhibit cancer cell migration, suppress AKT phosphorylation, thereby inhibiting cell proliferation, and induce apoptosis through caspase-3/7 activation [61].